ADI-14448
ADI-14448 is a RSV prefusion fusion glycoprotein inhibitor and HMPV fusion glycoprotein inhibitor, with a Kd of 3.8 × 10-10 M for RSV preF. ADI-14448 binds to epitope III of RSV preF, thereby blocking viral infection. ADI-14448 neutralizes RSV subtype A and HMPV subtype A1. ADI-14448 can be used in studies related to respiratory syncytial virus infection and metapneumovirus infection.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Virus
ADI-14448 binds specifically to pre-fusion RSV F (DS-Cav1) with high affinity, with an apparent Kd of 3.8 × 10-10 M, and does not bind to post-fusion RSV F (F DFP)[1].
ADI-14448 (subjected to serial four-fold dilutions from 1:10 to 1:163,840; pre-incubated with virus for 1 h prior to incubation with HEp-2 cells for 22-24 h) potently neutralizes RSV subtype A (strain A2) in HEp-2 cells, with an IC50 of 0.04 μg/mL[1].
ADI-14448 (serial dilutions; 36 h) potently neutralizes the HMPV A1 sublineage (NL/1/00) in Vero-118 cells, with an IC50 of 0.05 μg/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
/ [NCBI]
P03420
HRSV F0/F Protein
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)